• ChemFaces is a professional high-purity natural products manufacturer.
  • Product Intended Use
  • 1. Reference standards
  • 2. Pharmacological research
  • 3. Inhibitors
  • Home
  • Natural Products
  • Bioactive
  • Screening Libraries
  • Hot Products
  • Plant Catalog
  • Customer Support
  • Product Use Citation
  • About Us
  • Contact Us
  • Natural Products
    CAS No. 67979-25-3 Price $118 / 20mg
    Catalog No.CFN99732Purity>=98%
    Molecular Weight330.29Type of CompoundAnthraquinones
    FormulaC17H14O7Physical DescriptionPowder
    Download Manual    COA    MSDSSimilar structuralComparison (Web)
    How to Order
    Orders via your E-mail:

    1. Product number / Name / CAS No.
    2. Delivery address
    3. Ordering/billing address
    4. Contact information
    Sent to Email: info@chemfaces.com
    Contact Us
    Order & Inquiry & Tech Support

    Tel: (0086)-27-84237683
    Fax: (0086)-27-84254680
    E-mail: manager@chemfaces.com
    Address: No. 83, CheCheng Rd., WETDZ, Wuhan, Hubei 430056, PRC
    Delivery time
    Delivery & Payment method

    1. Usually delivery time: Next day delivery by 9:00 a.m. Order now

    2. We accept: Wire transfer & Credit card & Paypal & Western Union
    * Packaging according to customer requirements(5mg, 10mg, 20mg and more). We shipped via FedEx, DHL, UPS, EMS and others courier.
    Our products had been exported to the following research institutions and universities, And still growing.
  • Pennsylvania State University (USA)
  • Centralised Purchases Unit (CPU)... (India)
  • Instituto Politécnico de Bragan?a (Portugal)
  • Calcutta University (India)
  • Agricultural Research Organizati... (Israel)
  • Universidade Católica Portuguesa (Portugal)
  • University of Dicle (Turkey)
  • Auburn University (USA)
  • University of Medicine and Pharm... (Romania)
  • Leibniz Institute of Plant Bioch... (Germany)
  • University of Beira Interior (Portugal)
  • More...
  • Package
    Featured Products

    Catalog No: CFN99907
    CAS No: 517-88-4
    Price: $80/20mg
    Kushenol X

    Catalog No: CFN92390
    CAS No: 254886-77-6
    Price: $568/5mg
    Kushenol C

    Catalog No: CFN92391
    CAS No: 99119-73-0
    Price: $468/10mg
    Mulberroside F

    Catalog No: CFN90794
    CAS No: 193483-95-3
    Price: $398/10mg
    Arteannuin B

    Catalog No: CFN98807
    CAS No: 50906-56-4
    Price: $228/20mg
    Biological Activity
    Description: Aurantio-obtusin possesses anti-allergic, vasorelaxation, hypotensive and hypolipidemic effects, it is a promising osteoanabolic compound with potential therapeutic applications in the prevention of osteoporosis and other metabolic bone diseases. Aurantio-obtusin can inhibit allergic responses in IgE-mediated mast cells and anaphylactic models, it suppresses degranulation, histamine production, and reactive oxygen species generation and inhibits the production and mRNA expression of tumor necrosis factor-α and interleukin-4, and also suppresses the prostaglandin E2 production and expression of cyclooxygenase 2.
    Targets: TNF-α | NO | Akt | NOS | PI3K | Serine | COX | ROS | PGE | IL Receptor
    In vitro:
    J Agric Food Chem. 2015 Oct 21;63(41):9037-46.
    Cassia tora Seed Extract and Its Active Compound Aurantio-obtusin Inhibit Allergic Responses in IgE-Mediated Mast Cells and Anaphylactic Models.[Pubmed: 26434611 ]
    Cassia tora seed is widely used due to its various biological properties including anticancer, antidiabetic, and anti-inflammatory effects. However, there has been no report of the effects of C. tora seed extract (CTE) on immunoglobulin E (IgE)-mediated allergic responses.
    In this research, we demonstrated the effects of CTE and its active compound Aurantio-obtusin on IgE-sensitized allergic reactions in mast cells and passive cutaneous anaphylaxis (PCA). CTE and Aurantio-obtusin suppressed degranulation, histamine production, and reactive oxygen species generation and inhibited the production and mRNA expression of tumor necrosis factor-α and interleukin-4. CTE and Aurantio-obtusin also suppressed the prostaglandin E2 production and expression of cyclooxygenase 2. Furthermore, CTE and Aurantio-obtusin suppressed IgE-mediated FcεRI signaling such as phosphorylation of Syk, protein kinase Cμ, phospholipase Cγ, and extracellular signal-regulated kinases. CTE and Aurantio-obtusin blocked mast cell-dependent PCA in IgE-mediated mice.
    These results suggest that CTE and Aurantio-obtusin are a beneficial treatment for allergy-related diseases.
    Planta Med. 2014 May;80(7):544-9.
    Aurantio-obtusin stimulates chemotactic migration and differentiation of MC3T3-E1 osteoblast cells.[Pubmed: 24841966]
    Osteoporosis is one of the major metabolic bone diseases and is among the most challenging noncommunicable diseases to treat. Although there is an increasing interest in identifying bioactive molecules for the prevention and management of osteoporosis, such studies principally focus only on differentiation and mineralization of osteoblasts or inhibition of osteoclast activity. Stimulation of osteoblast migration must be a promising osteoanabolic strategy for improved metabolic bone disease therapy.
    In this study, we show that an anthraquinone derivative, Aurantio-obtusin, stimulated chemotactic migration of MC3T3-E1 osteoblast cells in a concentration-dependent manner. The use of a real-time chemotaxis analyzing system, TAXIScan, facilitated the evaluation of both velocity and directionality of osteoblast migration in response to the compound. Besides migration, the compound stimulated osteoblast differentiation and mineralization.
    Taken together, the data presented in this paper demonstrate that Aurantio-obtusin is a promising osteoanabolic compound of natural origin with potential therapeutic applications in the prevention of osteoporosis and other metabolic bone diseases.
    In vivo:
    Journal of Analytical Science,2016, 32(2):178-82.
    Metabolomics-based Study of the Lipid Regulating Effect of Aurantio-obtusin on Hyperlipidemia Rats.[Reference: WebLink]
    The influences of Aurantio-obtusin on endogenous metabolites in blood of hyperlipemia rats were investigated by metabonomics method in order to find the related biomarkers.
    The rat model was established by hyperlipidemia rats that were raised by high fat diet and then treated with intragastric administration of Aurantio-obtusin.Metabolites in plasma of hyperlipidemia rats were accurately analyzed by gas chromatography-mass spectrometry.In order to find out the potential biomarkers,principal component analysis,partial least squares discriminant analysis and random forest algorithm were used to study the changes of endogenous metabolite profiles in rats before modeling after modeling and after drug treatments.Ten potential biomarkers were obtained as the final achievement:alanine,glycine,valine,isoleucine,fumaric acid,serine,1,5-anhydro-D-ghlcitol,linoleic acid,stearic acid and cholesterol.
    This investigation demonstrates that aurantio has a good lipid regulating effect mainly by affecting the body amino acid and fatty acid metabolism.
    Aurantio-obtusin Description
    Source: The seeds of Cassia obtusifolia L.
    Solvent: Chloroform, Dichloromethane, Ethyl Acetate, DMSO, Acetone, etc.
    Storage: Providing storage is as stated on the product vial and the vial is kept tightly sealed, the product can be stored for up to 24 months(2-8C).

    Wherever possible, you should prepare and use solutions on the same day. However, if you need to make up stock solutions in advance, we recommend that you store the solution as aliquots in tightly sealed vials at -20C. Generally, these will be useable for up to two weeks. Before use, and prior to opening the vial we recommend that you allow your product to equilibrate to room temperature for at least 1 hour.

    Need more advice on solubility, usage and handling? Please email to: service@chemfaces.com

    After receiving: The packaging of the product may have turned upside down during transportation, resulting in the natural compounds adhering to the neck or cap of the vial. take the vial out of its packaging and gently shake to let the compounds fall to the bottom of the vial. for liquid products, centrifuge at 200-500 RPM to gather the liquid at the bottom of the vial. try to avoid loss or contamination during handling.
    Recent ChemFaces New Products and Compounds

    Catalog No: CFN95063
    CAS No: 161099-37-2
    Price: $333/5mg

    Catalog No: CFN98160
    CAS No: 548-37-8
    Price: $218/20mg

    Catalog No: CFN92172
    CAS No: 22688-79-5
    Price: $318/10mg
    Viscumneoside III

    Catalog No: CFN89421
    CAS No: 118985-27-6
    Price: $288/10mg
    Vicenin -3

    Catalog No: CFN92032
    CAS No: 59914-91-9
    Price: $218/10mg

    Catalog No: CFN93257
    CAS No: 2608-21-1
    Price: $368/5mg
    Magnoloside A

    Catalog No: CFN99232
    CAS No: 113557-95-2
    Price: $318/5mg
    20-O-Glucoginsenoside Rf

    Catalog No: CFN95036
    CAS No: 68406-27-9
    Price: $368/10mg
    Recently, ChemFaces products have been cited in many studies from excellent and top scientific journals

    Cell. 2018 Jan 11;172(1-2):249-261.e12.
    doi: 10.1016/j.cell.2017.12.019.

    PMID: 29328914

    Mol Cell. 2017 Nov 16;68(4):673-685.e6.
    doi: 10.1016/j.molcel.2017.10.022.

    PMID: 29149595

    Scientific Reports 2017 Dec 11;7(1):17332.
    doi: 10.1038/s41598-017-17427-6.

    PMID: 29230013

    Molecules. 2017 Oct 27;22(11). pii: E1829.
    doi: 10.3390/molecules22111829.

    PMID: 29077044

    J Cell Biochem. 2018 Feb;119(2):2231-2239.
    doi: 10.1002/jcb.26385.

    PMID: 28857247

    Phytomedicine. 2018 Feb 1;40:37-47.

    PMID: 29496173
    Calculate Dilution Ratios(Only for Reference)
    1 mg 5 mg 10 mg 20 mg 25 mg
    1 mM 3.0276 mL 15.1382 mL 30.2764 mL 60.5528 mL 75.6911 mL
    5 mM 0.6055 mL 3.0276 mL 6.0553 mL 12.1106 mL 15.1382 mL
    10 mM 0.3028 mL 1.5138 mL 3.0276 mL 6.0553 mL 7.5691 mL
    50 mM 0.0606 mL 0.3028 mL 0.6055 mL 1.2111 mL 1.5138 mL
    100 mM 0.0303 mL 0.1514 mL 0.3028 mL 0.6055 mL 0.7569 mL
    * Note: If you are in the process of experiment, it's need to make the dilution ratios of the samples. The dilution data of the sheet for your reference. Normally, it's can get a better solubility within lower of Concentrations.
    Kinase Assay:
    J Pharmacol Sci. 2015 Jul;128(3):108-15.
    Aurantio-obtusin relaxes systemic arteries through endothelial PI3K/AKT/eNOS-dependent signaling pathway in rats.[Pubmed: 26076958 ]
    Aurantio-obtusin is a natural effective compound isolated from Semen Cassiae, which possesses hypotensive and hypolipidemic effects. Although its hypotensive effect have been clarified, mechanisms Aurantio-obtusin relaxes systemic arteries remain unclear. This study was to investigate effects and mechanisms of Aurantio-obtusin on isolated mesenteric arteries (MAs).
    We examined MAs relaxation induced by Aurantio-obtusin on rat isolated MAs, expression and activity of endothelial nitric oxide synthase (eNOS) and protein kinase B (AKT), and nitric oxide (NO) production in bovine artery endothelial cells (BAECs). Findings showed Aurantio-obtusin elicited dose-dependent vasorelaxation with phenylephrine (PE) precontracted rat MA rings (diameter: 200-300 μm), which can be diminished by denudation of endothelium and inhibition of eNOS activity, while having no effect on rat isolated pulmonary artery (PA) rings. Aurantio-obtusin increased NO production by promoting phosphorylations of eNOS at Ser-1177 and Thr-495 in endothelial cells. Aurantio-obtusin also promoted phosphorylations of Akt at Ser-473. PI3K inhibitor LY290042 could diminish vasorelaxation induced by Aurantio-obtusin. Moreover Aurantio-obtusin also elicited dose-dependent vasorelaxation effect with PE precontracted MA rings (diameter: 100-150 μm). Therefore, vasorelaxation induced by Aurantio-obtusin was dependent on endothelium integrity and NO production, which mediated by endothelial PI3K/Akt/eNOS pathway.
    Results suggest Aurantio-obtusin may offer therapeutic effects in hypertension, as a new potential vasodilator.
    Animal Research:
    Phytother Res. 2014 Oct;28(10):1577-80.
    Biotransformation of glucoaurantio-obtusin towards aurantio-obtusin increases the toxicity of irinotecan through increased inhibition towards SN-38 glucuronidation.[Pubmed: 24842785]
    The present study aims to investigate the influence of irinotecan's toxicity by the biotransformation of glucoAurantio-obtusin to Aurantio-obtusin.
    Intraperitoneal administration (i.p.) of 100 mg/kg Aurantio-obtusin significantly increased the toxicity of irinotecan, but the i.p. administration of 100 mg/kg glucoAurantio-obtusin showed negligible influence towards irinotecan's toxicity. Furthermore, the mechanism was explained through determining the inhibition potential of glucoAurantio-obtusin and Aurantio-obtusin towards the glucuronidation metabolism of SN-38 that has been regarded to be the major active product responsible for the toxicity of irinotecan. The results showed that Aurantio-obtusin exhibited strong competitive inhibition towards the glucuronidation of SN-38, but negligible inhibition potential of glucoAurantio-obtusin towards SN-38 glucuronidation was observed.
    These results showed that biotransformation of glucoAurantio-obtusin towards Aurantio-obtusin increased the toxicity of irinotecan through increased inhibition of SN-38 glucuronidation.